Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR

Federated Hermes Inc. trimmed its holdings in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 28.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,544,437 shares of the company’s stock after selling 4,122,163 shares during the quarter. Federated Hermes Inc. owned 10.76% of aTyr Pharma worth $7,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in ATYR. Millennium Management LLC increased its holdings in shares of aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after purchasing an additional 1,231,052 shares during the period. Goldman Sachs Group Inc. increased its holdings in aTyr Pharma by 46.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company’s stock worth $1,155,000 after buying an additional 120,496 shares during the period. ProShare Advisors LLC acquired a new stake in aTyr Pharma during the 2nd quarter valued at approximately $90,000. Geode Capital Management LLC boosted its holdings in shares of aTyr Pharma by 126.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock valued at $10,639,000 after acquiring an additional 1,170,276 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of aTyr Pharma in the second quarter worth $101,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.25.

aTyr Pharma Trading Up 3.8%

ATYR stock opened at $0.88 on Monday. The business’s 50-day moving average is $0.75 and its 200 day moving average is $2.16. aTyr Pharma, Inc. has a 12-month low of $0.64 and a 12-month high of $7.29. The stock has a market cap of $86.51 million, a price-to-earnings ratio of -1.06 and a beta of 0.59.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.91 million. As a group, equities analysts forecast that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

aTyr Pharma Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.